The Literature
Nov 2, 2026
•
10 min read
End-of-induction MRD below 0.01% in pediatric B-ALL, St Jude's single-tube 38-parameter spectral panel, and auto-gating trained by EVE Online players.
Oct 28, 2026
8 min read
Naive-like T cells in 580 axi-cel products, flow MRD before blinatumomab in Ph+ ALL, and a stem-cell gate for MDS relapse after transplant.
Industry Moves
Oct 23, 2026
6 min read
Three CD19 CAR-Ts report MS data, China drafts cell and gene therapy export limits, and Thermo Fisher's academic sales stay flat.
Special Editions
Oct 21, 2026
4 min read
What lands in your inbox each week, a sample of every edition, and how FlowCytoNews is made with AI and cited sources.
Oct 16, 2026
Legend's in vivo CAR-T gets a US IND; Labcorp buys most of BioReference for $722M; Agilent buys Proscia
On the Calendar
Oct 14, 2026
3 min read
CYTO 2027 abstracts open Oct 19; ASH discount ends Oct 21; a crowded November from SITC to flowcytometryUK
Oct 12, 2026
Flow MRD as an early endpoint in 2,623 AML patients; a synthetic myeloma assay control; why DLBCL biopsies come back flow-negative
Oct 9, 2026
5 min read
CellCarta and Waters team up on flow CDx; ARUP builds a flow foundation model; Caribou steps back from allogeneic CAR-T
Oct 7, 2026
What small-particle cytometers really claim, why up to two-thirds of clinical EV counts were unreliable, and five checks before you report one
